Investigating how a protein called FoxP1 affects lung disease in COPD
Role of FBXO24 mediated ubiquitination of FoxP1 protein in the pathogenesis and treatment of COPD
This study is looking at how a protein called FoxP1 affects lung health in people with Chronic Obstructive Pulmonary Disease (COPD), especially how it breaks down in response to cigarette smoke, to help find new ways to treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10873025 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the FoxP1 protein in the development of Chronic Obstructive Pulmonary Disease (COPD). It examines how the protein is regulated through a process called ubiquitination, which leads to its degradation in lung cells, particularly in response to cigarette smoke. By analyzing data from various cohorts and conducting laboratory experiments, the research aims to uncover the mechanisms by which FoxP1 influences lung health and disease progression. The ultimate goal is to identify potential therapeutic targets for COPD treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with COPD, particularly those with a history of smoking.
Not a fit: Patients with COPD who do not have a history of smoking or those with other unrelated lung conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that modify the progression of COPD and improve patient outcomes.
How similar studies have performed: While the specific role of FoxP1 in COPD is being explored for the first time, similar research has shown promise in understanding protein regulation in other diseases.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Chandra, Divay — University of Pittsburgh at Pittsburgh
- Study coordinator: Chandra, Divay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.